How much weight can I expect to lose with Wegovy?

In the STEP 1 clinical trial, patients lost an average of 14.9% of their body weight over 68 weeks (about 15 months). However, individual results vary significantly — some patients lose 20% or more, while others lose less than 5%. About one-third of participants achieved 20% or greater weight loss. Wegovy works best when combined with dietary changes and regular physical activity.

What happens if I stop taking Wegovy?

The STEP 1 extension study showed that most patients regained approximately two-thirds of their lost weight within one year of stopping semaglutide. This is because the appetite-suppressing effects reverse when the medication is discontinued. Wegovy is intended as a long-term, potentially indefinite treatment — similar to how blood pressure medications must be continued to maintain their effect.

Will my insurance cover Wegovy?

Coverage varies significantly by insurance plan. Many commercial insurers now cover Wegovy with prior authorization (often requiring documented failure of diet/exercise and specific BMI criteria). Medicare Part D currently has limited coverage for anti-obesity medications. Check with your insurer and consider the manufacturer's patient assistance programs if coverage is denied.

Can I take Wegovy if I have type 2 diabetes?

Wegovy is approved for weight management regardless of diabetes status, but if you have type 2 diabetes, your doctor may prefer Ozempic (semaglutide for diabetes) instead, as it is specifically indicated and dosed for glycemic control. You should not take both Wegovy and Ozempic simultaneously, as they contain the same active ingredient.

What to Expect When Starting Semaglutide (Wegovy)

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Wegovy (semaglutide 2.4 mg injection) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with obesity (BMI >=30) or overweight (BMI >=27) with at least one weight-related comorbidity ^[1]. It works by acting on GLP-1 receptors in the brain to reduce appetite and food intake, and by slowing gastric emptying to increase satiety ^[2]. Wegovy is used alongside a reduced-calorie diet and increased physical activity. The landmark STEP clinical trials demonstrated average weight loss of 15-17% of body weight over 68 weeks.

Week-by-week timeline

Week 1-4GI side effects are usually mild to moderate and self-limiting. Eating smaller meals and avoiding greasy foods is the single most effective strategy.

Starting at 0.25 mg Weekly

You begin with 0.25 mg subcutaneous injection once weekly. This is a sub-therapeutic dose designed solely for GI tolerability [1]. Even at this low dose, many patients notice a reduction in appetite and food cravings within the first 1-2 weeks. Nausea is the most common side effect, reported in up to 44% of patients across the full dose-escalation period, though it is typically most noticeable in the first weeks at each new dose [3]. Other common effects include decreased appetite, diarrhea, vomiting, and constipation.

Month 2Weight loss varies widely between individuals. Focus on the trend over months, not weekly fluctuations.

Escalation to 0.5 mg Weekly

After 4 weeks, the dose increases to 0.5 mg weekly [1]. GI symptoms may briefly recur or intensify. You will likely notice more pronounced appetite suppression and reduced interest in calorie-dense foods. Early weight loss is partly due to reduced caloric intake and partly fluid shifts. It is common to lose 2-4% of body weight during the first 2 months, though individual results vary significantly.

Month 3-4If side effects are intolerable at a higher dose, your doctor may delay escalation by an additional 4 weeks at the current dose.

Escalation Through 1.0 mg and 1.7 mg

The dose escalates monthly: 1.0 mg at month 3 and 1.7 mg at month 4 [1]. Each increase may cause temporary GI effects that typically resolve within 1-2 weeks. Weight loss accelerates during this period as the appetite-suppressant effect intensifies. You may notice significant changes in portion sizes — feeling full after eating much less than before. Physical energy often improves as weight decreases.

Month 5+Weight loss plateaus are normal and do not indicate treatment failure. Maintaining lost weight is a major therapeutic success.

Maintenance Dose at 2.4 mg Weekly

The target maintenance dose of 2.4 mg weekly is typically reached by month 5 [1]. The STEP 1 trial demonstrated an average weight loss of 14.9% from baseline at 68 weeks (approximately 15 months) with this dose, compared to 2.4% with placebo [3]. The SELECT trial showed a 20% reduction in major cardiovascular events in overweight/obese adults without diabetes [4]. Weight loss generally continues for 12-18 months before plateauing. GI side effects have usually resolved by this stage.

When to call your doctor

Contact your healthcare provider if you experience:

Severe, persistent abdominal pain — especially if radiating to the back, which may indicate pancreatitis [1]
Signs of allergic reaction: rash, swelling of face/lips/tongue, difficulty breathing, or rapid heartbeat [1]
Persistent vomiting that prevents adequate fluid intake for more than 24 hours, risking dehydration [1]
Symptoms of gallbladder problems: severe pain in the upper right abdomen, fever, jaundice, or clay-colored stools — gallstones occur more frequently with rapid weight loss [1]
Mental health changes: new or worsening depression, suicidal thoughts, or unusual mood changes [1]

Tips for getting started

Inject Wegovy on the same day each week at any time of day, with or without meals. Rotate injection sites (abdomen, thigh, upper arm). Prioritize protein-rich foods to preserve lean muscle mass during weight loss — aim for at least 60-80 grams of protein daily ^[2]. Start with smaller, frequent meals to minimize nausea. Stay well hydrated (at least 64 oz of water daily). Engage in regular physical activity — both aerobic exercise and resistance training — to support metabolic health and preserve muscle mass during weight loss. Store unused pens in the refrigerator; the pen in use can be kept at room temperature for up to 28 days ^[1].

Frequently asked questions

More about Semaglutide (Wegovy)

Semaglutide (Wegovy) drug guideSide effects, dosage, interactions, and more Semaglutide (Ozempic) vs Semaglutide (Wegovy)Compare these medications Semaglutide (Wegovy) vs Tirzepatide (Zepbound)Compare these medications Semaglutide (Wegovy) vs Liraglutide (Saxenda)Compare these medications Semaglutide (Wegovy) & MetforminInteraction details

References

[Regulatory] Wegovy (semaglutide) injection FDA Prescribing Information. Novo Nordisk. Revised 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf Accessed 2025-01-15.
[Regulatory] Semaglutide. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/ Accessed 2025-01-15.
[Clinical] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ Accessed 2025-01-15.
[Clinical] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: March 1, 2026